Crystalvue Medical (6527) reported revenue of NT$98.7 million for Oct 2026, +12.3% year on year and +17.2% from the previous month. Revenue for Jan–Oct 2026 was NT$726.1 million (-5.7% year on year).
Revenue for Oct 2026 was a record high (previous high: Dec 2025, NT$98.4 million). →
In Oct 2026, it ranked No. 74 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$98.7 million | +12.3% | +17.2% |
| Sep 2026 | NT$84.3 million | +9.8% | +31.7% |
| Aug 2026 | NT$64 million | -2.8% | -12.5% |
| Jul 2026 | NT$73.1 million | +25.2% | +6.3% |
| Jun 2026 | NT$68.7 million | -17.4% | -21.4% |
| May 2026 | NT$87.5 million | -4.4% | +42.1% |
| Apr 2026 | NT$61.6 million | -24.7% | -11.2% |
| Mar 2026 | NT$69.3 million | -17.6% | +55.8% |
| Feb 2026 | NT$44.5 million | -37.9% | -40.3% |
| Jan 2026 | NT$74.5 million | +8.5% | -24.3% |
| Dec 2025 | NT$98.4 million | +20.5% | +21.7% |
| Nov 2025 | NT$80.8 million | +14.9% | -8.1% |
| Oct 2025 | NT$87.9 million | +22.4% | +14.6% |
| Sep 2025 | NT$76.7 million | +9.7% | +16.5% |
| Aug 2025 | NT$65.8 million | -16.5% | +12.8% |
| Jul 2025 | NT$58.4 million | -30.8% | -29.8% |
| Jun 2025 | NT$83.2 million | +21.9% | -9.1% |
| May 2025 | NT$91.5 million | +30.9% | +12.0% |
| Apr 2025 | NT$81.7 million | +11.2% | -2.8% |
| Mar 2025 | NT$84.1 million | +27.6% | +17.3% |
| Feb 2025 | NT$71.7 million | +5.5% | +4.4% |
| Jan 2025 | NT$68.7 million | +4.4% | -15.9% |
| Dec 2024 | NT$81.6 million | +23.3% | +16.1% |
| Nov 2024 | NT$70.3 million | +14.5% | -2.1% |
| Oct 2024 | NT$71.9 million | +16.4% | +2.8% |
Jan–Oct 2026 cumulative: NT$726.1 million (-5.7% YoY)
Other Biotech & Medical companies
Compare with peers: Crystalvue Medical vs PEC / Crystalvue Medical vs Lotus Pharm / Crystalvue Medical vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16